Jocelyn Mohs, PharmD

Carboplatin is a platinum-analog alkylating agent that plays a role in treating several types of malignancies, often being preferred to its relative cisplatin due to its favorable toxicity profile and ease of delivery. The major dose-limiting toxicity of carboplatin is myelosuppression, especially thrombocytopenia. The major route of elimination of carboplatin is through the kidneys, and subsequently it requires a downward dose adjustment for patients with impaired renal function to prevent severe hematologic toxicity.